This is a working overview of peptide analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-27 and is reviewed periodically as new material appears.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | typical of a lyophilised peptide preparation |
| Solubility behaviour | pH dependent | lowest near the isoelectric point |
| Storage of bulk material | Minus 20 degrees Celsius or below | protect from light and moisture |
| Storage of unused pen | 2 to 8 degrees Celsius | do not freeze |
| Common assay method | Reversed-phase HPLC | identity, purity and content |
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
government experiment that infected hundreds of Guatemalans with syphilis". A previous suit against the United States government was dismissed in 2011 for the Guatemala syphilis experiments when a judge determined that the U.S. government could not be held liable for actions committed outside of the U.S. An experiment was conducted by Vanderbilt University in the 1940s where they gave 800 pregnant women radioactive iron, 751 of which were pills, without their consent. In a 1969 article published in the American Journal of Epidemiology, it was estimated that three children had died from the experiment.
In men and women, the sole requirement for being considered a dwarf is having an adult height of 147 cm (4 ft 10 in) or less, and it is almost always sub-classified with respect to the underlying condition that is the cause of the short stature. Dwarfism is usually caused by a genetic variant; achondroplasia is caused by a mutation on chromosome 4. If dwarfism is caused by a medical disorder, the person is referred to by the underlying diagnosed disorder. Disorders causing dwarfism are often classified by proportionality. Disproportionate dwarfism describes disorders that cause unusual proportions of the body parts, while proportionate dwarfism results in a generally uniform stunting of the body. Disorders that cause dwarfism may be classified according to one of hundreds of names, which are usually permutations of the following roots:
A Hahn echo decay experiment can be used to measure the dephasing time, as shown in the animation. The size of the echo is recorded for different spacings of the two pulses. This reveals the decoherence that is not refocused by the 180° pulse. In simple cases, an exponential decay is measured which is described by the T2 time.
Sources: en.wikipedia.org
where V is the measure of the volume in contact with the fluid, that is the volume of the submerged part of the body, since the fluid doesn't exert force on the part of the body which is outside of it. The magnitude of buoyancy force may be appreciated a bit more from the following argument. Consider any object of arbitrary shape and volume V surrounded by a liquid. The force the liquid exerts on an object within the liquid is equal to the weight of the liquid with a volume equal to that of the object. This force is applied in a direction opposite to gravitational force, that is of magnitude:
The Swiss Federal Tribunal (SFT) has decided not to entertain the appeal filed by the players against the CAS award of 11 January 2016, imposing a 2-year ban on each player following an anti-doping rule violation. The SFT determined that since the players did not formally challenge the jurisdiction of CAS during the arbitration procedure and accepted the application of the CAS Rules (including the rule providing for a de novo hearing, i.e. for a procedure allowing the CAS to conduct a full review of the case), they had lost their right to challenge the CAS jurisdiction in appeal. The SFT added that, even if the players had properly challenged the jurisdiction of CAS, CAS jurisdiction in this matter would have been confirmed, and the appeal would have been dismissed. The players did not seek an injunction against their suspensions when appealing with the Federal Supreme Court, meaning that they would have served their 2016 suspensions even if the guilty verdicts had been cleared. This was to eliminate any risk that a new, two-year period of suspension could be ordered to be served in full if the appeal were unsuccessful.
=== Targeted drug delivery systems === Targeted drug delivery systems facilitate the selective delivery of therapeutic agents to specific disease sites while minimizing off-target effects. These systems employ strategies, such as nanoparticles, liposomes, and micelles, to encapsulate drugs and enhance their stability, solubility, and bioavailability. By incorporating diagnostic components, such as imaging agents or targeting ligands, into these delivery systems, clinicians can monitor drug distribution and accumulation in real-time, ensuring effective treatment and reducing systemic toxicity. Targeted drug delivery systems hold promise in the treatment of cancer, cardiovascular diseases, and other conditions, as they allow for personalized and site-specific therapy.
Sources: en.wikipedia.org
Ice formation concentrates solutes and can mechanically stress the peptide or damage the delivery device. Thawing afterwards may leave aggregates that are not visible to the eye. Refrigeration keeps the solution above its freezing point while slowing chemical degradation.
Size-exclusion chromatography is the most common technique, separating monomer from dimer and higher-order species by hydrodynamic volume. It is usually paired with ultraviolet detection and, for trace work, with multi-angle light scattering. Results depend on mobile-phase conditions, so method details matter when comparing datasets.
The detailed degradation profile under real-world temperature excursions and repeated handling is not fully described in the open literature. Relative contributions of photo-degradation versus thermal pathways are also incompletely mapped. Whether specific impurity species carry different biological activity is an open question rather than an established finding.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.